Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 2 results out of 2
Data Insights
NM-002 by Novabiotics for Community Acquired Pneumonia: Likelihood of Approval
NM-002 is under clinical development by Novabiotics and currently in Phase III for Community Acquired Pneumonia. According to GlobalData, Phase...
Data Insights
NP-213 by Novabiotics for Onychomycosis (Tinea Unguium): Likelihood of Approval
NP-213 is under clinical development by Novabiotics and currently in Phase II for Onychomycosis (Tinea Unguium). According to GlobalData, Phase...